Updated Therapy of Malignant Hyperthermia

  • Uwe Schulte-Sasse
Conference paper


Anesthesia mortality is remarkably low [1], and thus mass disasters can be discounted. Therefore, it is our task today to analyze rare adverse outcomes [2] so that we can identify some basic, still existing causes for morbidity and mortality and thus be able to overcome thses dangers and approach the infinitely distant goal of zero mortality in our speciality. Regarding safety in anesthesia, the words of an American anesthetist should be quoted [3]:

We don’t need more powerful narcotics! We don’t need more sophisticated formulas for the kinetic modeling! We don’t need more studies to substantiate the studies that verified the studies that supported the studies that proved something in 1969! What we desperately need is information about how to better use the data and devices we already have!


Malignant Hyperthermia Malignant Hyperthermia Mass Disaster Respiratory Minute Volume Procaine Amide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Campling EA, Devlin HB, Hoile RW, Lunn JN (1992) The report of the national confidential enquiry into perioperative deaths 1990. National Confidential Enquiry into Perioperative Deaths, London, pp 120–121Google Scholar
  2. 2.
    Ellis FR (1992) Detecting susceptibility to malignant hyperthermia. Br Med J 304: 791CrossRefGoogle Scholar
  3. 3.
    Vitez TS (1989) Comment on: The incidence of venous air embolism during total arthroplasty. Sury Anesth 33: 133Google Scholar
  4. 4.
    Kolb ME, Home ML, Martz R (1982) Dantrolene inhuman malignant hyperther-mia. A multicenter study. Anesthesiology 56: 254–262CrossRefGoogle Scholar
  5. 5.
    Ryan JF (1993) Malignant hyperthermia. In: Coté CJ, Ryan JF, Todres ID, Goudsouzian NG (eds) A practice of anesthesia for infants and children, 2nd edn. Saunders, Philadelphia, pp 151–170Google Scholar
  6. 6.
    Rosenberg H, Fletcher J, Seitman D (1992) Pharmacogenetics. In: Barash PG, Cullen BF, Stoelting RK (eds) Clinical anesthesia, 2nd edn. Lippincott, Philadelphia, pp 589–613Google Scholar
  7. 7.
    Better OS, Stein JH (1990) Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 322: 825–829PubMedCrossRefGoogle Scholar
  8. 8.
    Malignant Hyperthermia Association of the United States (1993) Emergency therapy for malignant hyperthermia.Google Scholar
  9. 9.
    Schulte-Sasse U, Eberlein HJ (1991) Reasons for the persistence of a high mortality due to malignant hyperthermia and proposals for its reduction. Anaesthesiol Reanimat 16: 202–207Google Scholar
  10. 10.
    Fukui T, Morio M, Fujji K, Kikuchi H, Ohtani M, Kishida T, Kitoh S, Suemor I (1982) Effectiveness of dantrolene on rigid type of malignant hyperthermia with chronic recurrent course. Hiroshima J Anaesth 18 (Suppl 1): 41–48Google Scholar
  11. 11.
    Britt BA (1985) Malignant hyperthermia. Can Anaesth Soc J 32: 666–678PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Uwe Schulte-Sasse
    • 1
  1. 1.German Hotline for Malignant Hyperthermia Emergencies, Department of Anaesthesia Critical Care MedicineHeilbronn Community Hospital of the University of HeidelbergHeilbronnGermany

Personalised recommendations